← The record

Amino Acid Formula With Vitamins And Minerals Without Methionine And Supplemented With Arachidonic Acid And Docosahexaenoic Acid

Recommended MetabolicRestrictedNot applicable line

Dietary management of pyridoxine non-responsive homocystinuria (HCU), expected to be used in infants and young children from 6 months to 5 years of age.

1
Submissions
2023–23
On the record
ICER range
Cost-min
Cost basis

Decision on record

1 decision
  • Meeting Mar 2023 Recommended Pyridoxine non-responsive homocystinuria (HCU)

Access path

1 submission · public record
  1. Mar 2023
    Recommended · restricted

    vs HCU gel

  2. PBS listing · Restricted
RecommendedDeferredNot recommended

From the public summary

Verbatim · PSD text · may span indications
PBAC outcome
7.1 The PBAC recommended the General Schedule Restricted Benefit listing of amino acid formula with vitamins and minerals without methionine and supplemented with arachidonic acid (ARA) and docosahexaenoic acid (DHA) (HCU explore5) for the dietary management of pyridoxine non-responsive homocystinuria (HCU) under the same circumstances as HCU gel, except with a maximum quantity of 8 cartons rather than 4 cartons to provide the same number of grams of PE.PSD · Mar 2023
7.2 The PBAC considered that HCU explore5 should be cost-minimised to the lowest cost comparator accepted by the NPWP (HCU gel, HCU Anamix infant or HCU Anamix Junior) at an equivalent price per gram of PE.PSD · Mar 2023
Economic analysis
5.9 The submission presented a cost-minimisation analysis of HCU explore5 compared with HCU gel and HCU cooler 10, based on the same price per gram of PE of $1.33 at the approved ex-manufacturer price (AEMP) (Table 2). 5PSD · Mar 2023
Clinical claim
5.6 The submission claimed non-inferior comparative effectiveness and non-inferior comparative safety of HCU explore5 compared with HCU gel. The submission provided a comparison of the nutritional profile of HCU explore5 with HCU gel presented as Table 1.PSD · Mar 2023
5.7 The PBAC advised HCU explore5 is expected to provide a non-inferior clinical benefit for the management of HCU compared to the comparators identified.PSD · Mar 2023

Cost-effectiveness

Cost-minimisation analysis; no ICER calculated by design.

The PBAC considered that HCU explore5 should be cost-minimised to the lowest cost comparator accepted by the NPWP (HCU gel, HCU Anamix infant or HCU Anamix Junior) at an equivalent price per gram of PE. PBAC · 2023
Price cut / RSA needed

Decision context

PopulationInfants and young children from 6 months to 5 years of age with pyridoxine non-responsive homocystinuria.

Submission history

1 entries
DecidedOutcomeComparatorICEREvidence
Mar 2023 Recommended · restricted HCU gel Cost-minimisation · Cost-minimisation

Similar precedents

By decision profile